Certara Inc(CERT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.02 | Insider Own | 36.33% | Shs Outstand | 152.5M | Perf Week | 11% |
| Market Cap | 1.71B | Forward P/E | 28.21 | EPS next Y | 16.71% | Insider Trans | - | Shs Float | 97.1M | Perf Month | 21.74% |
| Enterprise Value | 1.83B | PEG | 112.86 | EPS next Q | 0.09 | Inst Own | 77.77% | Short Float | 26.44% | Perf Quarter | 38.27% |
| Income | -0.00B | P/S | 4.18 | EPS this Y | -22.7% | Inst Trans | 0.17% | Short Ratio | 8.92 | Perf Half Y | 82.71% |
| Sales | 0.41B | P/B | 1.77 | EPS next 5Y | 0.25% | ROA | -1.31% | Short Interest | 25.68M | Perf YTD | 27.13% |
| Book/sh | 6.34 | P/C | 9.28 | EPS past 3/5Y | - 50.19% | ROE | -1.89% | 52W High | -8.87% ($12.29) | Perf Year | -3.28% |
| Cash/sh | 1.21 | P/FCF | 21.25 | Sales past 3/5Y | 7.66% 11.45% | ROIC | -0.23% | 52W Low | 151.69% ($4.45) | Perf 3Y | -8.72% |
| Dividend Est. | - | EV/EBITDA | 19.84 | EPS Y/Y TTM | -134.07% | Gross Margin | 48.49% | Volatility(W/M) | 5.5% 5.61% | Perf 5Y | -72.89% |
| Dividend TTM | - | EV/Sales | 4.47 | Sales Y/Y TTM | 0.66% | Oper. Margin | 4.63% | ATR (14) | 0.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.55 | EPS Q/Q | 642.62% | Profit Margin | -0.72% | RSI (14) | 69.47 | Recom | 2.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.55 | Sales Q/Q | -10.81% | SMA20 | 13.86% ($9.84) | Beta | 1.34 | Target Price | $9.17 |
| Payout | - | Debt/Eq | 0.31 | Earnings | 2026/11/5 | SMA50 | 24.86% ($8.97) | Rel Volume | 0.96 | Prev Close | $11.48 |
| Employees | 1576 | LT Debt/Eq | 0.31 | EPS/Sales Surpr. | -10.41% -4.91% | SMA200 | 54.28% ($7.26) | Avg Volume(3M) | 2.88M | Price | $11.2 |
| IPO | 2020/12/11 | Option/Short | Yes/Yes | Trades | 16421 | Volume | 2,748,916 | Change | -2.44% |
💊 Certara is a healthcare information services company that provides biosimulation software and model-based drug development services. It helps pharmaceutical and biotech clients predict the efficacy and safety of drug candidates at the clinical stage using computer models, and is expanding its applications into animal health, crop science, medical devices, and the public sector.
Over the past 1 year, on the higher side
9% below its 1-year high.
Traded about as much as usual. That is 96% of its average volume.
Next earnings report: November 5
6 days to go.
CERT keeps an operating profit but posts a net loss
Of every $100 in sales, $4.63 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -22.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $418. Peers typically go for $181. Compared with its own 1-year average, it is 35% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -72.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.4% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #11 of 41 in the industry
Based on market cap of $2B.
FAQ
What kind of company is CERT?
CERT belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of CERT?
The market cap of CERT is approximately $1.7B, ranking 2,201 within its sector.
What is the 52-week high and low for CERT?
CERT has recorded a 52-week high of $12.29 and a low of $4.45.
